Acquired Aplastic Anemia Companies

Novartis receives FDA approval for Cosentyx® (secukinumab) for treating moderate-to-severe AA in adults who have failed previous immunosuppressive therapy.

Apellis Pharmaceuticals introduces APL-2 (pegcetacoplan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a condition often associated with AA, offering a potential new therapy option.

Regen Biopharma presents promising data from a Phase 2 clinical trial of REGN410, a novel immunosuppressive drug, demonstrating positive early results in AA patients

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) partners with pharmaceutical companies and research institutions to fund clinical trials and accelerate development of new AA treatments.

The European Hematology Association (EHA) collaborates with researchers to develop standardized treatment guidelines and improve care for AA patients across Europe.

List of Acquired Aplastic Anemia Key Companies in the Market

• Pfizer Inc. (U.S.)


• Bayer AG (Germany)


• Novo Nordisk AS (Dernmark)


• Shire (Republic of Ireland)


• SOBI (Sweden)


• Octapharma (Switzerland)


• CSL Limited (Australia)


• Amgen Inc.


• GlaxoSmithKline plc.


• Bluebird bio.